Breaking New Ground: Unleashing Canine EEG Capabilities for Enhanced Research at Transpharmation Canada.

We are thrilled to announce a new addition to our arsenal of cutting-edge capabilities at Transpharmation Canada. With the pursuit of scientific excellence and innovation at the core of our mission, we have taken a bold step forward in expanding our offerings to better serve our clients and advance the frontiers of research.

Introducing Canine EEG: Unravelling Drug-induced Neurophysiological Changes in the Dogs

We are delighted to unveil our newest asset: Canine Electroencephalography (EEG) capabilities that allow us to gain deeper insights into the neurological effects of novel compounds in our canine companions, facilitating profound advancements in pharmaceutical and biomedical research. The addition of canine EEG represents our steadfast commitment to staying at the forefront of scientific innovation and providing our clients with the most comprehensive research solutions available.

Sleep-Wake Profiling of Compounds: Characterising Canines’ Sleep-Wake Architecture

Sleep is a vital physiological process and is crucial for maintaining overall health and wellbeing. With our new canine EEG capabilities, we can now offer unparalleled sleep-wake profiling of compounds. This means we can assess the impact of pharmaceutical agents on the sleep patterns of canines, helping to identify potential sleep disturbances or therapeutic benefits. The ability to monitor and analyse sleep-wake cycles in canines opens the door to a deeper understanding of drug effects and safety profiles.

Quantitative EEG (QEEG): Unlocking Objective Neurophysiological Measurements

Objective measurement is the cornerstone of scientific research, and the same applies to canine EEG studies. Our QEEG capabilities enable us to derive precise and quantitative data from canine brain oscillatory activity. By quantifying the changes in EEG power spectra, we can objectively evaluate the effects of compounds on canine brain oscillations and identify potential correlations with behavioural and physiological responses. This quantitative approach significantly enhances the reliability and precision of our research outcomes.

Electrocardiogram (ECG): Integrating Cardiac Monitoring for Comprehensive Assessments

To bolster our commitment to comprehensive research, we are pleased to incorporate canine ECG alongside EEG. The simultaneous monitoring of EEG and ECG allows us to assess the potential impact of pharmaceutical agents on both the central nervous system and cardiac activity in canines. This integration enhances our ability to study compound safety and the potential risk of cardiac adverse events.

Seizure Liability Assessment: Advancing Canine Neurological Safety Studies

Seizure liability is a critical aspect of drug safety evaluation. With our canine EEG capabilities, we can meticulously investigate the seizure threshold of compounds, providing crucial data to assess their safety in terms of neurological adverse effects. This proactive approach to seizure liability assessment empowers our clients to make informed decisions early in the drug development process, saving valuable time and resources.

Ethical Considerations and Animal Welfare

As we embark on this new phase of research, it is essential to emphasize our commitment to upholding the highest standards of animal welfare and ethical research practices. Our use of canine subjects is undertaken with the utmost care and consideration for their well-being. We prioritize their comfort, provide expert veterinary care, and adhere to strict ethical guidelines to ensure their welfare throughout the studies.

Collaboration and Advancement

We extend our gratitude to all team members whose dedication and expertise made the implementation of canine EEG capabilities possible. This achievement is a testament to the collaborative spirit and relentless pursuit of excellence that defines our organization.

The Future of Canine Research is Here

With the launch of our canine EEG capabilities, we embark on an exciting journey of exploration and discovery in canine neurophysiology. This transformational addition strengthens our commitment to offering the most advanced and comprehensive research services to our valued clients in the pharmaceutical and biomedical industries.

Together, we will continue to push the boundaries of scientific knowledge, improve drug development, and enhance the lives of our canine companions and their human counterparts.